Amino Acid, Peptide, or Protein – Page 6

GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics

1 month ago talkbio0Tagged Antisense Oligonucleotides, Antistreptolysin O, CAMP4, Collaboration, gene upregulation, Kidney Diseases, LRPAP1 gene, milestone payments, Neurodegenerative Disorders, Platform, regulatory RNA, RNA therapeutics, royalties, SmithKline Beecham

GSK; CAMP4 Therapeutics; RNA therapeutics; regulatory RNA; antisense oligonucleotides; ASO; RAP Platform; neurodegenerative diseases; kidney disease; renal disease; gene upregulation; biotech collaboration; licensing deal; milestone payments; tiered royalties

Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study

1 month ago talkbio0Tagged Approved, Clinical Trials, Eli, Glucagon-Like Peptide 1, injectable incretins, national priority review voucher, Obesity, Oral cavity, orforglipron, Phase 3 trial, United States Food and Drug Administration, Wegovy, weight maintenance, Zepbound

Eli Lilly; orforglipron; oral GLP-1; FDA approval; national priority review voucher; ATTAIN-MAINTAIN trial; obesity treatment; weight maintenance; Zepbound; Wegovy; injectable incretins; Phase 3 trial

Exclusive: Compounding giant Empower Pharmacy cuts hundreds of staff, stops New Jersey operations

1 month ago talkbio0Tagged compounding pharmacy, East Windsor facility, Empower Pharmacy, Facility (object), Glucagon-Like Peptide 1, Inspection (procedure), layoffs, manufacturing shutdown, New Jersey operations, Outsourcing, Qualitative form, United States Food and Drug Administration, Workforce reduction

Empower Pharmacy; compounding pharmacy; layoffs; job cuts; New Jersey operations; East Windsor facility; manufacturing shutdown; outsourcing facility; FDA inspection; Form 483; compounded GLP-1 drugs; workforce reduction

Padcev-Keytruda Combination Succeeds Again in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

1 month ago talkbio0Tagged EV-304, Event-Free Survival, KEYNOTE-B15, Keytruda, Malignant neoplasm of urinary bladder, Padcev

Padcev; Keytruda; bladder cancer; KEYNOTE-B15; EV-304; event-free survival

FDA Commissioner Makary Addresses COVID-19 Vaccine Safety Concerns Amid Internal Debates and Investigations

1 month ago talkbio0Tagged Cautionary Warning, COVID19 (disease), Marty Makary, mRNA Vaccines, Myocarditis, RFK gene, Safety, United States Food and Drug Administration, vaccine deaths, Vaccines

Marty Makary; FDA; COVID-19 vaccine; myocarditis; vaccine deaths; safety warnings; RFK Jr.; mRNA vaccines

Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites

1 month ago talkbio0Tagged 2025, Acquisition, Acquisitions, fibroblast growth factor 21, Health care facility, Johnson & Johnson Intra-Cellular, M&A, MASH, Merck Verona, Patent Cliff, Pharma, pharma patent expirations, Sanofi Blueprint Medicines

pharma M&A 2025; biotech acquisitions; patent cliff; pharma patent expirations; Novo Nordisk Akero deal; Johnson & Johnson Intra-Cellular acquisition; Merck Verona Pharma deal; Sanofi Blueprint Medicines acquisition; FGF21 MASH deals; 2025 healthcare deals

GSK wins FDA approval for ultra-long-acting asthma drug Exdensur (depemokimab)

1 month ago talkbio0Tagged Approved, Asthma, biology (field), Depemokimab, dosing, eosinophilic, Exdensur, IL-5 Inhibitor, Phenotype, Severe (severity modifier), SmithKline Beecham, twice-yearly, type 2 inflammation, ultra-long acting, United States Food and Drug Administration

GSK; Exdensur; depemokimab; FDA approval; severe asthma; ultra-long-acting biologic; twice-yearly dosing; type 2 inflammation; eosinophilic phenotype; IL-5 inhibitor

RTW-backed startup Yarrow Bioscience signs autoimmune antibody deal with China’s GenSci

1 month ago talkbio0Tagged anti-TSHR antibody, Antibodies, Autoimmune, Changchun GeneScience Pharmaceutical, China, GenSci, GS-098, Investments, RTW, strategic partnership, Thyroid associated opthalmopathies, Yarrow Bioscience, YB-101

RTW Investments; Yarrow Bioscience; GenSci; Changchun GeneScience Pharmaceutical; autoimmune; antibody; GS-098; YB-101; anti-TSHR antibody; thyroid eye disease; China; ex-China rights; strategic partnership; licensing deal